JNJ
Johnson & Johnson
NYSE: JNJ · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$227.19
-1.16% today
Updated 2026-05-01
Market cap
$547.28B
P/E ratio
26.31
P/S ratio
5.68x
EPS (TTM)
$8.64
Dividend yield
2.28%
52W range
$142 – $252
Volume
8.0M
WallStSmart proprietary scores
59
out of 100
Grade: C+
Hold
Investment rating
4.7
Growth
C6.0
Quality
B9.0
Profitability
A+3.3
Valuation
D4/9
Piotroski F-Score
Moderate
2.6
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →203 stocks currently score above 75
Price targets
Analyst target
$252.42
+11.11%
12-Month target
$299.87
+31.99%
Intrinsic (DCF)
$160.43
Margin of safety
-41.61%
5 Strong Buy9 Buy10 Hold0 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 21.80% — above average
+ ROE 26.40% — strong efficiency
+ Free cash flow $1.47B — positive
Risks
- 41.61% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $79.99B | $85.16B | $88.82B | $94.19B | $96.36B | $101.7B |
| Net income | $17.94B | $35.15B | $14.07B | $26.80B | $5.24B | — |
| EPS | — | — | — | — | $8.64 | $11.65 |
| Free cash flow | $17.18B | $18.25B | $19.84B | $19.70B | $1.47B | — |
| Profit margin | 22.43% | 41.28% | 15.84% | 28.46% | 21.80% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-10 | WOODS, EUGENE A. | Buy | 155 | $242.14 |
| 2026-03-10 | PINTO, DANIEL E | Buy | 129 | $242.14 |
| 2026-03-10 | HEWSON, MARILLYN A | Buy | 206 | $242.14 |
Peer comparison
Smart narrative
Johnson & Johnson trades at $227.19. representing a P/E of 26.31x trailing earnings. Our Smart Value Score of 59/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.64, it sits in the grey zone. TTM revenue stands at $96.36B. with profit margins at 21.80%. Our DCF model estimates intrinsic value at $160.43.
Frequently asked questions
What is Johnson & Johnson's stock price?
Johnson & Johnson (JNJ) trades at $227.19.
Is Johnson & Johnson overvalued?
Smart Value Score 59/100 (Grade C+, Hold). DCF value $160.43.
What is the price target of Johnson & Johnson (JNJ)?
The analyst target price is $252.42, representing +11.1% upside from the current price of $227.19.
What is the intrinsic value of Johnson & Johnson (JNJ)?
Based on our DCF model, intrinsic value is $160.43, a -41.6% margin of safety versus $227.19.
What is the future stock price of JNJ by 2030?
Our research-backed model estimates Johnson & Johnson could reach $227.19 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Johnson & Johnson's revenue?
TTM revenue is $96.36B.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
2.64 — grey zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio5.68x
ROE26.40%
Beta0.33
50D MA$239.21
200D MA$205.59
Shares out2.41B
Float2.40B
Short ratio—
Avg volume8.0M
Performance
1 week+0.82%
1 month-6.52%
3 months-1.02%
YTD+10.36%
1 year+49.55%
3 years+52.68%
5 years—